Johnson & Johnson Announces First Quarter Results Report Increased by 7.9% Year-on-year

On April 20, Johnson & Johnson released its first quarter 2021 performance report, with sales of 22.
3 billion US dollars, a strong increase of 7.
9% over the same period last year.

US market sales were 11.
111 billion U.
S.
dollars, an increase of 3.
9%;

International market sales amounted to USD 11.
21 billion, an increase of 12.
2%
.

After excluding the net impact of acquisitions, divestitures, and exchange rate conversions, based on business operations, global sales increased by 3.
9%, US sales increased by 8.
2%, and international sales increased by 6.
0%
.

       Divided by business, sales of consumer health care business were US$3.
543 billion, pharmaceutical business sales were US$12.
199 billion, and medical device business sales were US$6.
579 billion.
Excluding the net impact of acquisitions and divestitures, adjusted operations decreased by 2.
3 compared with the same period last year.
%, an increase of 7.
4%, an increase of 8.
8%
.

       In the first quarter report, Johnson & Johnson raised the adjusted annual operating sales growth guidance value for 2021 to 9.
3%, and adjusted the mid-term operating earnings per share growth to 16.
8%
.

       In terms of the pharmaceutical business, divided by disease areas, immunology sales were 3.
914 billion US dollars (an increase of 5.
5%), oncology sales were 3.
57 billion US dollars (an increase of 14.
6%), neuroscience sales were 1.
721 billion US dollars (an increase of 1.
6%), infectious diseases Disease sales were US$1.
007 billion (up 7.
1%), pulmonary hypertension sales were US$861 million (up 13.
7%), and Cardiovascular & Metabolism & Other sales were US$1.
127 billion (down 4.
1%)
.

       Among them, a number of drugs in the immunology business performed strongly, including Stelara (increased by 9.
4%) and Tremfya (increased by 46.
3%), but Remicade fell by 21.
7%, and Simponi/Simponi Aria fell by 5.
9%
.

       In the pulmonary hypertension business, Opsumit and Uptravi performed strongly, increasing by 18.
5% and 21.
9% respectively
.

       In the report, Johnson & Johnson also counted the pipeline and business updates in the first quarter of 2021:

       - Regulatory approval: Ponvory was approved by the FDA for the treatment of relapsing multiple sclerosis; the single-dose COVID-19 vaccine was approved by the EU, included in the emergency use list by the WHO, and granted emergency use by the US FDA; Spravato was approved by the EU for use Severe depression patients with psychiatric emergencies quickly relieve depression; single-focus intraocular lenses TECNIS EYHANCE and TECNIS EYHANCE TORIC II IOLS have been approved by the US FDA for the treatment of cataracts

       -Regulatory submission: ViiV submitted a supplementary application to the US FDA to expand the use of Cabenuva as an HIV treatment drug every 2 months

       ——Other: An update on the Phase 3 ACIS study evaluating Erleada combined with Zytiga and prednisone in the treatment of castration-resistant prostate cancer (mCRPC) patients; and the African Vaccine Access Trust (AVAT) reached a single-dose COVID-19 vaccine purchase Agreement; Ponvory's treatment of relapsing multiple sclerosis received positive opinions from EU CHMP; CAR-T cell therapy cilta-cel was accepted in Europe and included in the accelerated evaluation for the treatment of multiple myeloma

       Reference source: Johnson & Johnson Reports 2021 First-Quarter Results